Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
10321 Results for "
in
" in MedChemExpress (MCE) Product Catalog:
Products (10321)
10321 Results for "in" in MCE Product Catalog:
60
60 Publications Verification
Synonyms: JNK inhibitor XVI
JNK-IN-8 (JNK Inhibitor XVI) is a potent JNK inhibitor with IC50s of 4.7 nM, 18.7 nM, and 1 nM for JNK1, JNK2, and JNK3, respectively .
40
Research Areas:
TRULI (Lats-IN-1) is a potent and ATP-competitive inhibitor of Lats1 and Lats2 kinases. TRULI promotes Yap-dependent proliferation in postmitotic mammalian tissues .
34
34 Cited Publications
STAT5-IN-1 is a STAT5 inhibitor with an IC50 of 47 μM for STAT5β isoform.
31
31 Cited Publications
Target:
Research Areas:
PKM2-IN-1 (compound 3k) is a pyruvate kinase M2 (PKM2) inhibitor with an IC50 of 2.95 μM .
31
31 Cited Publications
Cat. No.: HY-P7077
Purity: ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: IL2; T Cell Growth Factor; interleukin 2; Aldesleukin; IL-2; involved in Regulation Of T-Cell Clonal Expansion; TCGF; T-Cell Growth Factor; interleukin-2; Lymphokine
Species:
Mouse
Source:
E. coli
29
29 Cited Publications
Research Areas:
GCN2-IN-1 is a potent general control nonderepressible 2 kinase (GCN2) inhibitor with an IC50 of <0.3 μM in the enzyme assay and an IC50 of 0.3-3 μM in the cell assay .
26
26 Cited Publications
Cat. No.: HY-12836
CAS No.: 844882-93-5
Target:
Research Areas:
IFN alpha-IFNAR-IN-1 is a nonpeptidic, low-molecular-weight inhibitor of the interaction between IFN-α and IFNAR. IFN alpha-IFNAR-IN-1 inhibits modified Vaccinia virus ankara (MVA)-induced IFN-α responses in murine bone-marrow-derived, Flt3- L-differentiated pDC cultures (BM-pDCs) (IC50=2-8 μM) .
26
26 Cited Publications
Target:
Research Areas:
IFN alpha-IFNAR-IN-1 hydrochloride is a nonpeptidic, low-molecular-weight inhibitor of the interaction between IFN-α and IFNAR. IFN alpha-IFNAR-IN-1 hydrochloride inhibits modified Vaccinia virus ankara (MVA)-induced IFN-α responses in murine bone-marrow-derived, Flt3- L-differentiated pDC cultures (BM-pDCs) (IC50=2-8 μM) .
24
24 Cited Publications
Cat. No.: HY-P7037
Purity: ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: IL2; T Cell Growth Factor; interleukin 2; Aldesleukin; IL-2; involved in Regulation Of T-Cell Clonal Expansion; TCGF; T-Cell Growth Factor; interleukin-2; Lymphokine
Species:
Human
Source:
E. coli
22
22 Cited Publications
Synonyms: RMC-6236; RAS-in-2
Daraxonrasib (RMC-6236) is an orally active, non-covalent RAS (ON) inhibitor. Daraxonrasib disrupts the interaction of wild-type or mutant RAS proteins with the RAS binding domain of BRAF, with EC50 values ranging from 28-220 nM for wild-type KRAS, NRAS, HRAS, and multiple oncogenic RAS variants. Daraxonrasib inhibits pERK. Daraxonrasib has anti-tumor activity against KRAS mutant tumors .
21
21 Cited Publications
Target:
Research Areas:
Fumarate hydratase-IN-1 (compound 2) is a cell-permeable fumarate hydratase inhibitor. Fumarate hydratase-IN-1 has antiproliferative activity against several cancer cell lines with a mean IC50 of 2.2 μM .
21
21 Cited Publications
Cat. No.: HY-50737A
CAS No.: 924296-19-5
Target:
Research Areas:
DUB-IN-2 is a potent deubiquitinase inhibitor with an IC50 of 0.28 μM for USP8 .
19
19 Cited Publications
Vps34-IN-1 is a potent and selective inhibitor of class III Vps34 PI3K. Vps34-IN-1 inhibits phosphorylation of PtdIns by recombinant insect cell expressed Vps34-Vps15 complex with an IC50 of ~25 nM. Vps34-IN-1 can suppress SGK3 activation by reducing PtdIns(3)P levels via lowering phosphorylation of T-loop and hydrophobic motifs. Vps34-IN-1 modulates autophagy .
17
17 Cited Publications
Research Areas:
p38 MAPK-IN-1 (Compound 4) is a novel potent and selective inhibitor of p38 MAPK with IC50 of 68 nM. p38 MAPK-IN-1 shows sustained levels, low clearance and good bioavailability.
16
15
15 Cited Publications
Target:
Research Areas:
TLR4-IN-C34 is an orally active TLR4 inhibitor and reduces systemic inflammation in models of endotoxemia and necrotizing enterocolitis .
13
13 Cited Publications
Research Areas:
STING-IN-2 (C-170) is a potent and covalent STING inhibitor. STING-IN-2 efficiently inhibits both mouse STING (mmSTING) and human STING (hsSTING). STING-IN-2 can be used for autoinflammatory disease research .
13
13 Cited Publications
Cat. No.: HY-B0608
CAS No.: 18472-51-0
Research Areas:
Chlorhexidine digluconate (20% in water) is a orally active cationic antimicrobial agent that targets microbial cell membranes. Chlorhexidine digluconate (20% in water) binds to cell membrane phospholipids non-specifically, destroys membrane structure and induces leakage of cell contents. Chlorhexidine digluconate (20% in water) has broad-spectrum bactericidal activity against both Gram-positive and Gram-negative bacteria. Chlorhexidine digluconate (20% in water) can interfere with membrane permeability, cause protein precipitation and energy metabolism disorders, such as rapid inhibition of microbial growth and induction of cell death (necrosis or apoptosis) .
12
12 Cited Publications
Target:
Research Areas:
OPN-IN-1 is an osteopontin (OPN) expression inhibitor. OPN-IN-1 has potential anti-breast cancer cell metastasis activity and can be used in the study of cancer .
12
12 Cited Publications
Target:
Research Areas:
Nrf2-IN-1 is an inhibitor of nuclear factor-erythroid 2-related factor 2 (Nrf2). Nrf2-IN-1 is developed for the research of acute myeloid leukemia (AML) .
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
